Harry Finch


SVP Therapeutics, Pulmagen & NED

Harry has many years' experience in drug discovery, development and medicinal chemistry in the pharmaceutical and biotechnology industry, and is SVP, Therapeutics, of Pulmagen Therapeutics. He has a PhD in organic chemistry, following which he worked at Ciba-Geigy, Roche and Allen & Hanburys, before joining GlaxoWellcome where he became Director of Chemistry. In addition to expertise in the respiratory area (Harry is a co-inventor of GSK’S successful asthma drug salmeterol (Serevent)), he has worked across a range of therapeutic areas and at several biotechnology companies. Harry is a non-executive director of Conformetrix.

Funding Partners: